



SFw image

PATENT  
Attorney Docket No. 056291-5245

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **BARLAAM *et al.***

Application No.: 10/572,794

Group Art Unit: *Unassigned*Filed: **March 21, 2006**Examiner: *Unassigned*For: **QUINAZOLINE DERIVATIVES  
AS ANTIPROLIFERATIVE AGENTS**Date: **September 13, 2006**Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Window, **Mail Stop Amendment**  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)****Citation of Technically Related U.S. Patent Applications**

The Examiner's attention is directed to the following technically related U.S. patents or applications of Applicants' assignee:

Inventor	U.S. Serial No. Filing Date	U.S. Patent No. Issue Date	PCT Publication No. PCT Publication Date
Bradbury <i>et al.</i>	10/508,675 September 22, 2004		WO 03/082831 October 9, 2003
Hennequin <i>et al.</i>	10/555,085 October 31, 2005		WO 2004/096226 November 11, 2004
Hennequin	10/566,841 February 2, 2006		WO 2005/013998 February 17, 2005
Bradbury <i>et al.</i>	10/571,991 March 15, 2006		WO 2005/028469 March 31, 2005
Bradbury <i>et al.</i>	10/572,048 March 15, 2006		WO 2005/028470 March 31, 2005
Hennequin <i>et al.</i>	10/572,261 March 16, 2006		WO 2005/026157 March 24, 2005
Hennequin <i>et al.</i>	10/572,303 March 17, 2006		WO 2005/026156 March 24, 2005
Hennequin <i>et al.</i>	10/573,090 March 15, 2006		WO 2005/026150 March 24, 2005

Inventor	U.S. Serial No. Filing Date	U.S. Patent No. Issue Date	PCT Publication No. PCT Publication Date
Bradbury et al.	10/573,352 March 24, 2006		WO 2005/030757 April 7, 2005
Delouvrie et al.	10/586,965 25-Jul-2006		WO 2005/075439 August 18, 2005
Bradbury et al.	10/857,342 June 1, 2004		
Hennequin et al.	11/443,395 May 31, 2006		WO 03/040109 May 15, 2003

With the exception of U.S. 10/857,342 (U.S. Publication No. 20050165035, copy not provided), a copy of the specification and claims for each application, in the form of the published PCT application from which such application was filed is being filed herewith. Consideration of each listed application is earnestly solicited.

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants request the Examiner to consider this Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Information Disclosure Statement.

With the exception of U.S. Patents and Publication, copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


**Except** for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due

under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a

**CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R.

§1.136(a)(3).

Respectfully Submitted,  
**Morgan Lewis & Bockius LLP**



Date: September 13, 2006  
Morgan Lewis & Bockius LLP  
Customer No. 09629  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
Tel. No.: 202-739-3000

By:

Donald J. Bird  
Registration No. 25,323  
Tel. No.: (202) 739-5320  
Fax No.: (202) 739-3001



**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

Attorney Docket No.  
056291-5245Application No.  
10/572,794Applicants: **BARLAAM**PTO Form 1449  
September 13, 2006Filing Date: **March 21, 2006**1624  
Group Art Unit **1624****U.S. PATENT DOCUMENTS**

Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date
---------	--------------	------	------	-------	-----------	-------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

**FOREIGN PATENT DOCUMENTS**

	Document No.	Date	Country	Class	Sub-Class	Translation
35.	WO 98/02434	January 22, 1998	WIPO			
36.	WO 98/13354	April 2, 1998	WIPO			
37.	WO 99/06378	February 11, 1999	WIPO			
38.	WO 99/35132	July 15, 1999	WIPO			
39.	WO 00/18740	April 6, 2000	WIPO			
40.	WO 00/24718	May 4, 2000	WIPO			
41.	WO 00/44728	August 3, 2000	WIPO			
42.	WO 00/55141	September 21, 2000	WIPO			
43.	WO 00/56720	September 28, 2000	WIPO			
44.	WO 01/07432	February 1, 2001	WIPO			
45.	WO 01/21596	March 29, 2001	WIPO			
46.	WO 01/21597	March 29, 2001	WIPO			
47.	WO 01/77085	October 18, 2001	WIPO			
48.	WO 01/98277	December 27, 2001	WIPO			
49.	WO 02/24684	March 28, 2002	WIPO			
50.	WO 02/30924	April 18, 2002	WIPO			
51.	WO 02/34744	May 2, 2002	WIPO			
52.	WO 02/41882	May 30, 2002	WIPO			
53.	WO 02/44166	June 6, 2002	WIPO			
54.	WO 02/48117	June 20, 2002	WIPO			
55.	WO 02/056882	July 25, 2002	WIPO			
56.	WO 02/066445	August 29, 2002	WIPO			EP 1 369 418
57.	WO 02/068409	September 6, 2002	WIPO			
58.	WO 02/073235	September 19, 2002	WIPO			
59.	WO 02/076976	October 3, 2002	WIPO			
60.	WO 02/092577	November 21, 2002	WIPO			
61.	WO 02/092578	November 21, 2002	WIPO			
62.	WO 02/097490	December 5, 2002	WIPO			
63.	WO 03/024448	March 27, 2003	WIPO			
64.	WO 03/040109	May 15, 2003	WIPO			
65.	WO 03/049740	June 19, 2003	WIPO			
66.	WO 03/082290	October 9, 2003	WIPO			US 20040048880
67.	WO 03/082831	October 9, 2003	WIPO			
68.	WO 2004/006846	January 22, 2004	WIPO			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)**

Examiner	/Tamthom Truong/	Date Considered	12/17/2009
----------	------------------	-----------------	------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

PTO Form 1449  
September 13, 2006Attorney Docket No.  
056291-5245Applicants: BARLAAM *et al.*

Filing Date: March 21, 2006

Application No.  
10/572,7941624  
Group Art Unit: 0635600X**U.S. PATENT DOCUMENTS**

Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

**FOREIGN PATENT DOCUMENTS**

	Document No.	Date	Country	Class	Sub-Class	Translation
69.	WO 2004/064718	August 5, 2004	WIPO			
70.	WO 2004/096226	November 11, 2004	WIPO			
71.	WO 2005/013998	February 17, 2005	WIPO			
72.	WO 2005/026150	March 24, 2005	WIPO			
73.	WO 2005/026156	March 24, 2005	WIPO			
74.	WO 2005/026157	March 24, 2005	WIPO			
75.	WO 2005/028469	March 31, 2005	WIPO			
76.	WO 2005/028470	March 31, 2005	WIPO			
77.	WO 2005/030757	April 7, 2005	WIPO			
78.	WO 2005/075439	August 18, 2005	WIPO			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)**

- |     |   |
|-----|---|
| 79. | Stamos <i>et al.</i> "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor" <i>J. Biol. Chem.</i> 277(48):46265-46272 (2002).   |
| 80. | Traxler <i>et al.</i> "Protein tyrosine kinase inhibitors in cancer treatment" <i>Exp. Opin. Ther. Patents</i> 7(6):571-588 (1997).   |
| 81. | Traxler <i>et al.</i> "Tyrosine kinase inhibitors in cancer treatment (Part II)" <i>Exp. Opin. Ther. Patents</i> 8(12):1599-1625 (1998).  |
| 82. | Tsou <i>et al.</i> "6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" <i>J. Med. Chem.</i> 44:2719-2734 (2001). |
| 83. | Vema <i>et al.</i> "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" <i>Bioorg Med Chem.</i> 11(21):4643-4653 (2003).   |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

Examiner

/Tamthom Truong/

Date Considered

12/17/2009

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.